Trevi Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
TRVI$14.91-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(Amounts in thousands, except share and per share amounts)
| Year Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $33,478 | $39,377 |
| General and administrative | 15,850 | 12,147 |
| Total operating expenses | 49,328 | 51,524 |
| Loss from operations | (49,328) | (51,524) |
| Other income (expense): | ||
| Interest income, net | 6,536 | 3,602 |
| Other expense, net | (31) | (15) |
| Interest expense | — | (4) |
| Total other income, net | 6,505 | 3,583 |
| Loss before income taxes | (42,823) | (47,941) |
| Income tax benefit | (64) | (30) |
| Net loss | $(42,759) | $(47,911) |
| Basic and diluted net loss per common share outstanding | $(0.32) | $(0.47) |
| Weighted average common shares used in net loss per share attributable to common stockholders, basic and diluted | 134,747,198 | 101,971,873 |
| Net loss | $(42,759) | $(47,911) |
| Other comprehensive income: | ||
| Net unrealized gains on available-for-sale marketable securities | 87 | 90 |
| Comprehensive loss | $(42,672) | $(47,821) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.